Barclays Maintains Overweight on Twist Bioscience, Lowers Price Target to $55
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Luke Sergott maintains an Overweight rating on Twist Bioscience (NASDAQ:TWST) but lowers the price target from $60 to $55.

August 05, 2024 | 11:48 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Barclays analyst Luke Sergott maintains an Overweight rating on Twist Bioscience but lowers the price target from $60 to $55.
The Overweight rating suggests a positive outlook, but the lowered price target indicates some caution. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100